Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

March 13, 2020

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

March 03, 2020

Jean Wright, MD, discusses key strategies in using radiation therapy to treat patients with breast cancer.

February 26, 2020

Julie R. Brahmer, MD, discusses targeted treatments for patients with oncogene-driven non–small cell lung cancer.

February 25, 2020

Tania Jain, MBBS, discusses the challenges with allogeneic transplant in patients with myelofibrosis.

February 22, 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

February 18, 2020

Jean Wright, MD, discusses the evolution of radiation oncology in early-stage breast cancer and how novel radiation modalities are poised to transform the field.

February 08, 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.

February 04, 2020

Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.

January 24, 2020

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

December 26, 2019

Ramy Sedhom, MD, looks back on his first year of oncology fellowship and shares advice for first-year fellows and trainees.

December 19, 2019

Research into the mechanisms that promote resistance to immune checkpoint blockade therapies suggests the need for new strategies for patients with immunorefractory disease.

November 14, 2019

Ashwani Rajput, MD, a cancer surgeon and researcher with a special interest in health care disparities, has been appointed director of the Kimmel Cancer Center at Johns Hopkins for the Washington, DC, region.

September 06, 2019

Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia harboring other common co-mutations or a high FLT3-internal tandem duplication allelic ratio.

May 30, 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the outlook for patients with oncogene-driven non–small cell lung cancer.

May 22, 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the benefits of liquid biopsies in non–small cell lung cancer.

March 29, 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the use of entrectinib in patients with NTRK-mutant and ROS1-rearranged non–small cell lung cancer.

March 13, 2019

Nilofer Saba Azad, MD, discusses data from 3 recent pivotal trials have influenced practice and/or warrant consideration when treating patients with localized pancreatic cancer.

March 11, 2019

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses considerations for managing immune-related adverse events in patients with non–small cell lung cancer.

March 06, 2019

Ana Maria Cristina De Jesus-Acosta, MD, discusses somatostatin analogs and peptide receptor radionucleotide therapy, and spoke to the discussion regarding the optimal sequence of therapy in patients with neuroendocrine tumors.

February 14, 2019

Julie R. Brahmer, MD, discusses advances made with immunotherapy in the lung cancer space, highlights challenges that still need to be addressed, and sheds light on ongoing research designed to determine treatment approaches beyond PD-1/PD-L1 and CTLA-4 inhibition